New class of HIV integrase inhibitors
that block viral replication in cell culture.
In addition, newer agents with novel mechanisms of action, such as HIV entry inhibitors (which inhibit the three steps of HIV entry: CD4 attachment, chemokine co-receptor binding and membrane fusion) and HIV integrase inhibitors
, are also under investigation.
HIV integrase inhibitors
with antiviral action are actively being studied.
Conformationally constrained tricyclic HIV integrase inhibitors
He also noted that there is now much excitement about HIV integrase inhibitors
, a major target for new drugs.
Human Immunodeficiency Virus HIV Protease Inhibitors HIV Non-nucleoside Reverse Transcriptase Inhibitors HIV Nucleoside Reverse Transcriptase Inhibitors HIV Entry Inhibitors HIV Integrase Inhibitors
Hepatitis C Virus Protease Inhibitors HCV Polymerase Nucleoside Inhibitors Other HCV Inhibitors Respiratory Syncytial Virus Inhibitors Influenza, Hepatitis B, and Cytomegalovirus Inhibitors
The Company's pipeline includes FV-100, its clinical-stage oral nucleoside analogue in development for the treatment of herpes zoster (shingles), as well as a series of HCV nucleoside polymerase inhibitors and HIV integrase inhibitors
BioAlliance Pharma SA (Paris:BIO), the specialty pharmaceutical company focused on the treatment of opportunistic infections in cancer and HIV, announces the presentation of its results on a new quinoline family acting as HIV integrase inhibitors
at the 16th Conference on Retroviruses and Opportunistic Infections (CROI), in Montreal, Canada (February 8 to 11, 2009).
a slight increase in revenues and a slight decrease in general and administrative expense, offset in part by an increase in research and development expenses associated with the clinical development of FV-100 and the preclinical development of its HCV nucleoside polymerase and HIV integrase inhibitors
and a decrease in net interest income in 2008.
4 million reduction in research and development expense associated with the settlement of prior litigation related to a production and supply agreement, a decrease in general and administrative expenses, and slightly higher revenue, offset by an increase in research and development expenditures associated with the clinical development of FV-100, as well as the preclinical development of the Company's HCV nucleoside polymerase inhibitors and HIV integrase inhibitors
and a decrease in net interest income.
In addition to FV-100, its oral nucleoside analogue in development for the treatment of herpes zoster (shingles), the Company's antiviral pipeline includes a series of HIV integrase inhibitors
and HCV polymerase inhibitors in preclinical development, and compounds active against cytomegalovirus (CMV).
The Company updated its 2008 financial guidance to reflect the clinical status of FV-100 and its preclinical development plans related to its HIV integrase inhibitors
and HCV polymerase inhibitors.